FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?

Radiation Oncology

Horst Urbach¹  Michael Maximilian Starke²  Tanja Schimek-Jasch²  Franziska Eckert³  Maximilian Niyazi⁴  Montserrat Carles⁵  Dimos Baltas⁵  Anca L. Grosu⁶  Michael Mix⁶  Ilinca Popp⁶ 

[1] Department of Neuroradiology, Medical Center, Faculty of Medicine, University of Freiburg;Department of Radiation Oncology, Medical Center, Faculty of Medicine, University of Freiburg;Department of Radiation Oncology, University Hospital Tübingen;Department of Radiation Oncology, University Hospital, LMU Munich;Division of Medical Physics, Department of Radiation Oncology, Medical Center, University of Freiburg;German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ);

关键词: Recurrent-glioblastoma;    FET-PET;    Radiomics;    Re-irradiation;   

DOI  :  10.1186/s13014-020-01744-8

来源: DOAJ

【 摘 要 】

Abstract Purpose The value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-positron emission tomography (PET)-radiomics in the outcome assessment of patients with recurrent glioblastoma (rGBM) has not been evaluated until now. The aim of this study was to evaluate whether a prognostic model based on FET-PET radiomics features (RF) is feasible and can identify rGBM patients that would most benefit from re-irradiation. Methods We prospectively recruited rGBM patients who underwent FET-PET before re-irradiation (GLIAA-Pilot trial, DRKS00000633). Tumor volume was delineated using a semi-automatic method with a threshold of 1.8 times the standardized-uptake-value of the background. 135 FET-RF (histogram parameters, shape and texture features) were extracted. The analysis involved the characterization of tumor and non-tumor tissue with FET-RF and the evaluation of the prognostic value of FET-RF for time-to-progression (TTP), overall survival (OS) and recurrence location (RL). Results Thirty-two rGBM patients constituted our cohort. FET-RF discriminated significantly between tumor and non-tumor. The texture feature Small-Zone-Low-Gray-Level-Emphasis (SZLGE) showed the best performance for the prediction of TTP (p = 0.001, satisfying Bonferroni-multiple-test significance level). Additionally, two radiomics signatures could predict TTP (TTP-radiomics-signature, p = 0.001) and OS (OS-radiomics-signature, p = 0.038). SZLGE and the TTP-radiomics-signature additionally predicted RL. Specifically, high values for TTP-radiomics-signature and for SZLGE indicated not only earlier progression, but also a RL within the initial FET-PET active volume. Conclusion Our findings suggest that FET-PET radiomics could contribute to the prognostic assessment and selection of rGBM-patients benefiting from re-irradiation. Trial registration DRKS00000633. Registered on 8th of December in 2010. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00000633 .

【 授权许可】

Unknown